Pay in 4 interest-free payments of $7.17 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
Adding more water (5 mL) increases the daily draw to 10 units (easier to measure) but does not solve the shelf-life problem
Boehringer Ingelheim Key Development Products Survodutide / BI 456906 GLP-1/glucagon receptor dual agonist Current Positioning Survodutide is a GLP-1/glucagon dual agonist discovered by Zealand Pharma and developed and commercialized by Boehringer Ingelheim
Emergency Treatments First, seek immediate medical attention in an emergency setting
Useful testing may include identity, potency, microbes, heavy metals, relevant impurities and stability
16% average weight loss is achieved in the first year* *Estimated result is based on the average weight loss self reported by Mochi members in their first year and is provided for illustrative purposes only
US$ 23.61
US$ 27.81
US$ 29.74
US$ 21.59
US$ 28.13
